Quark SEC Filing Provides New Details on Company Pipeline, Financials

The Israeli firm said that it intends to file two investigational new drug applications, one from its stable of in-house drug candidates and one from a collaboration with Japan's Nitto Denko, in 2012.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories